Europe Autoimmune Diagnostics Market

Europe Autoimmune Diagnostics Market Size (2023 to 2028)

The size of the Autoimmune Diagnostics Market in Europe was worth USD 3.78 billion in 2023 and estimated to reach USD 4.54 billion by the end of 2028, growing at a CAGR of 3.76%.

The rising prevalence of autoimmune diseases and the growing public awareness are expected to drive market value growth in the European region. Multiple Sclerosis is the most common autoimmune disease, and it affects 83 people in every 100,000 in Europe. Women are expected to be highly prone to multiple Sclerosis compared to men. Rheumatoid arthritis affects two million people across the region, followed by psoriasis. According to various studies, in the UK, females have a prevalence rate of 1.2%, and males have 0.4% of developing rheumatoid arthritis. Due to this, early diagnosis and onset of treatment play a crucial role in preventing permanent damage and disability. These factors demand autoimmune diagnostics, which enhances market growth.

The diagnostics results help confirm the disease and estimate the severity of the disease, which helps follow the disease's activity. The rising awareness of autoimmune diseases through research programs and various campaigns by the government and other organizations' collaborations. Several initiatives are being taken by the European Commission to bring complete awareness among the people regarding precautions, diagnosis, and treatment of autoimmune disorders. These reasons are fueling the growth of market revenue in the region.

The rising investments in the R&D activities by the market players and growing awareness among the people regarding the disease are influencing the researchers to focus on developing novel and accurate diagnostic tools, which will create lucrative growth opportunities for market expansion in the forecast period. The growing use of advanced technology in the European healthcare system is enhancing the adoption of technology in diagnostic tools and is estimated to provide market growth opportunities in the upcoming years.

MARKET RESTRAINTS:

The major restraining factor for the European Autoimmune diagnostics market growth is time consumption by the devices. Detection of autoimmune disorders takes time and requires various tests to confirm the disease. People from low economic backgrounds need to bear the expense of the tests. The diagnostic services for autoimmune diseases are expensive, which is expected to hamper the market growth. Another factor hindering the market expansion is the low accuracy of the tests. Most of the diagnostic blood tests for autoimmune disorders are only partially accurate. Sometimes, they show negative and false positive results, limiting market growth.

Most autoimmune disease diagnostic methods are still in research as no diagnostic test can diagnose the presence of an autoimmune disease with high precision, which is challenging for market expansion. The European Society of Blood and Marrow Transplantation for Immune Monitoring and Biobanking recommends SCT for severe autoimmune diseases, but many questions are still unanswered, which requires further research to improve the understanding of the mechanism.

Impact of COVID-19 on  Europe autoimmune diagnostics market:

The pandemic has had a massive impact on the European healthcare industry. The European countries have registered many COVID cases, influencing the healthcare system to consider only emergencies. Most of the autoimmune cases are kept aside by the healthcare. The implementation of the lockdown led to disruption in the supply chain, manufacturing, and production of diagnostic devices and test kits, which decreased sales, negatively impacting market growth. However, the pandemic has created awareness among people regarding health consciousness, which increased the early diagnosis of autoimmune diseases and is expected to increase the market growth in the forecast period.

This research report is on the European Autoimmune diagnostics market has been segmented & sub-segmented into the following categories:

By Test Type:

• Autoantibody Tests
• Antinuclear Antibody Tests
• Complete Blood Count (CBC)
• C-reactive protein (CRP) 
• Comprehensive Metabolic panel  
• Urinalysis 
• Erythrocyte Sedimentation Rate (ESR)     
• Others

The antinuclear antibody tests segment dominated the European market in 2023 and is expected to maintain its domination by holding the largest market share during the forecast period. Antinuclear antibody tests detect autoantibodies in the blood that attack healthy cells. The antibodies are formed before the actual disease occurs in the individual. This helps in early diagnosis of the disease by reducing the morbidity and mortality of the disease. The high prevalence of the autoimmune disease and the necessity of early diagnosis drive the market growth in this segment.

By Disease Type:

• Localized autoimmune disease diagnostics
  • Graves' Disease
  • Hashimoto's Thyroiditis
  • Multiple Sclerosis
  • Type 1 diabetes
  • Psoriasis
  • Others
• Systemic autoimmune disease diagnostics
  • Rheumatoid Arthritis (RA)
  • Ankylosing Spondylitis
  • Systemic Lupus Erythematosus (SLE)

The systemic autoimmune disease diagnostics segment held the most significant European market share in 2023. Systemic autoimmune diseases affect multiple organs, unlike localized ones, which only affect certain body regions or organs. Rheumatoid arthritis dominated the systemic autoimmune diseases by accounting for the highest number of cases and is expected to increase in the forecast period. According to the World Health Organization, in 2021, around 14 million people had rheumatoid arthritis. The United Kingdom has a prevalence rate of 1.2% in females and 0.4% in males. The extensive focus on the specificity and sensitivity of rheumatoid arthritis kits and supporting regulatory guidelines is expected to fuel the market growth.

By End User:

• Hospitals
• Research Centres
• Diagnostic Laboratories

The Diagnostic laboratories segment held the largest market share in 2023, the European autoimmune diagnostic market. The diagnostic laboratories consist of skilled professionals, and the availability of high-capacity equipment and the capacity to process numerous samples efficiently are boosting the market revenue in this segment.

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Europe held the second largest market share in the global market. Developed countries like the UK and Germany have the best healthcare infrastructure, and the rising prevalence of autoimmune diseases allows these countries to hold the largest regional market share. The increasing government initiatives to bring awareness among the people and implementation of reimbursement policies drive market growth in France and Italy. The growing technological advancements in diagnostics and increasing investments in R&D activities are boosting the market expansion in the region.

Companies leading the European Autoimmune disease market profiled in this report are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly and GlaxoSmithKline Plc.